OncoMatch/Clinical Trials/NCT07670026
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression
Is NCT07670026 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies multiple treatments including Sintilimab and Bevacizumab for glioblastoma.
Treatment: Sintilimab · Bevacizumab · Temozolomide — \*\*Brief Summary\*\* The goal of this clinical trial is to learn whether intensified adjuvant treatment is safe and may help delay disease progression in adults with high-risk newly diagnosed glioblastoma. High-risk newly diagnosed glioblastoma in this study includes glioblastoma that has been partially removed by surgery or glioblastoma that shows early progression or recurrence before postoperative radiotherapy. The main questions this study aims to answer are: * Does intensified adjuvant treatment improve median progression-free survival in participants with high-risk newly diagnosed glioblastoma? * How long do participants survive after receiving this treatment? * What medical problems do participants have during or after intensified adjuvant treatment? * How often do participants develop radiation necrosis? * How does this treatment affect participants' quality of life? Participants will: * Receive postoperative concurrent radiotherapy and temozolomide chemotherapy. * Receive a higher radiation dose to the residual tumor or early recurrent/progressive lesion, while standard radiation doses are given to the tumor bed and surrounding high-risk and low-risk areas. * Receive adjuvant temozolomide after concurrent chemoradiotherapy. * Receive sintilimab and bevacizumab by intravenous infusion once every 21 days for up to 1 year. * Have regular blood tests, biochemical tests, thyroid function tests, myocardial enzyme tests, electrocardiograms, and other safety assessments. * Have enhanced brain MRI scans regularly to evaluate disease status. * Be followed by clinic visits and/or telephone calls to collect information about disease progression, survival, side effects, later cancer treatments, and quality of life.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Glioblastoma
Prior therapy
Cannot have received: brain radiotherapy
Lab requirements
Blood counts
ANC >=1.5x10^9/L (1500/mm3), platelets >=75x10^9/L, hemoglobin >=9 g/dL (if bone marrow involvement: platelets >=50x10^9/L, ANC >=1.0x10^9/L, hemoglobin >=8 g/dL)
Kidney function
serum creatinine <=1.5x ULN
Liver function
serum bilirubin <=1.5x ULN, AST/ALT <=1.5x ULN (<=5x ULN if liver involvement)
Cardiac function
LVEF >=50% on cardiac function examination; INR <=1.5x ULN; PT and APTT <=1.5x ULN (unless on anticoagulant therapy and within expected range); NYHA class III or IV heart failure, unstable angina, severe poorly controlled ventricular arrhythmia, or ECG evidence of acute ischemia or MI within 6 months before screening [excluded]; QTcF interval >480 msec, unless secondary to bundle branch block [excluded]
Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07670026 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior brain radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages